Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Schering Plough highlights Zegerid as a “valuable addition” to OTC range

Schering Plough highlights Zegerid as a “valuable addition” to OTC range

13th March 2008

Schering Plough has highlighted Zegerid as a “valuable addition” to the company’s expanding portfolio of gastrointestinal over-the-counter (OTC) products.

John O’Mullane, group vice-president of research and development at Schering-Plough Consumer Health Care, compared Zegerid to its other product MiraLAX which was launched last year for the treatment of occasional constipation.

Mr O’Mullane’s comments arrive after the pharmaceutical firm announced the submission of a New Drug Application (NDA) to the US Food and Drug Administration for a 20 mg dosage of OTC Zegerid for the treatment of frequent heartburn.

The NDA was submitted under the terms of a licence agreement with Santarus, which was signed in October 2006 for the exclusive US and Canadian rights to market OTC Zegerid proton pump inhibitor (PPI) products using Santarus’ patented technology.

Under the agreement, Schering-Plough is responsible for the development, manufacture and commercialisation of Zegerid OTC products for heartburn-related indications in the US and Canada.

Santarus continue to manufacture and promote Zegerid as a prescription product for the US prescription market for PPI products.

Recently Schering-Plough suggested that sugammadex could “transform the practice of anaesthesia” through the improved management of muscle relaxation.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.